« Return to News | Drug Sponsors

Valeant approaches Cephalon with buyout offer

Wednesday, March 30, 2011 01:55 PM

Valeant Pharmaceuticals International, based in Canada, has made an unsolicited bid to buy U.S.-based Cephalon, a biopharmaceutical company, for $5.7 billion.

Valeant is bidding $73.00 per share in cash, which represents a premium of approximately 29% over Cephalon's 30-day trading average. Valeant group says it prefers "a consensual process" and has made "several private approaches" but "has been disappointed by Cephalon's unwillingness to engage in discussions in a timely manner," according to PharmaTimes.

Valeant chief executive Michael Pearson said "We have taken a close look at Cephalon's business and believe we put forward a very compelling offer." He added that "we are also committed to trying to find additional value if we are allowed to conduct due diligence."

Pearson said "we intend to be disciplined on price" and "if our offer does not have the requisite support of Cephalon's stockholders, we will focus our attention on other opportunities to invest our capital." However, he indicated that the bid could be increased after due diligence.

Cephalon’s board says it will consider the unsolicited proposal. In a letter to Pearson, chief executive of Cephalon Kevin Buchi said "your timing was propitious, since my management team was meeting last week to commence our long range planning process."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.